

I never doubted your education or expertise just wanted to know and have ammo if this guys asks.
I sent you an email. Need your address to send the DVD.
Moderator: Available
Not a problem, Kevin. I'm used to it in my world. Credentials are always being checked and re-checked - as they should be.Kevin Guse wrote:
I never doubted your education or expertise just wanted to know and have ammo if this guys asks.
No shokens in the rib. I might however hit you with an arthritic knee...Kevin Guse wrote:
I'm sure I'll catch a shoken in the ribs for that one in Boston.![]()
Actually, this thread is, or at least started out all about caffeine, not psychedelics, but its all good.fivedragons wrote:Rant mode is in the "on" position.
Since this thread is all about psychedelic drugs, I thought to mention that the infusion of LSD and other substances were introduced en masse to the American masses by the CIA.
IJ wrote:
Lycopene: no proof yet.
Don't even get me started on the idiots who are trying to use lycopene to treat people who ALREADY HAVE cancer. If you're trying to indict this phytonutrient via that "evidence" (or lack thereof), then you're barking up the wrong tree. Researchers decades ago showed that vitamin and phytonutrient therapy generally makes cancer cells grow faster. Duh!!Lycopene in the prevention of prostate cancer.
Dahan K, Fennal M, Kumar NB.
Department of Interdisciplinary Oncology, University of South Florida College of Medicine, Tampa, FL 33612-9416, USA.
Based on the evidence from epidemiologic, animal, and in vitro data and human clinical trials, it is evident that lycopene, a non-provitamin A carotenoid, is a promising agent for prostate cancer chemoprevention. It is also clear that the form of lycopene used (purified versus food sources), dose of lycopene and concomitant use with other carotenoids and antioxidants, duration of exposure, specific target populations, and stage of disease appear to play a major role in determining agonistic or antagonistic effects. Based on our review, there is enough evidence to warrant use of lycopene in phase I and II clinical trials to examine its safety and efficacy as a potential chemopreventive agent for prostate cancer. The objective of this article is to review this evidence from epidemiologic, animal, in vitro, and clinical trials and provide the need and rationale to examine further the role of lycopene for prostate cancer prevention.